RenovoRx, Inc.
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.04
- 52-Week Range
- $0.76 – $2.59
- Market Cap
- $54.04M
- P/E (TTM)
- —
- EPS (TTM)
- -0.31
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 5.80
- PEG Ratio
- —
- Return on Equity
- -149.98%
- Return on Assets
- -68.60%
- Gross Margin
- 84.04%
- Operating Margin
- -467.43%
- Profit Margin
- 0.00%
- Current Ratio
- 5.65
- Debt/Equity
- 0.04
- Total Debt
- $358.00K
- Free Cash Flow
- $-6.84M
- Revenue Growth
- 300.80%
- Earnings Growth
- —
- Enterprise Value
- $43.99M
Market Snapshot
About
RenovoRx is a clinical-stage biopharmaceutical company developing targeted combination therapies for high unmet medical need cancers. The company focuses on intra-arterial delivery technology that enables localized, intensive treatment of tumors while minimizing systemic exposure. RenovoRx is advancing its pipeline with a focus on pancreatic cancer and other solid tumors.